Canada Pension Plan Investment Board Blueprint Medicines Corp Transaction History

Canada Pension Plan Investment Board

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$41.06 - $66.48 $883,693 - $1.43 Million	21,522 New	21,522 $942,000
Q1 2022 May 13, 2022	SELL	$54.1 - $110.08 $334,500 - $680,624	-6,183 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$94.25 - $115.99 $29,406 - $36,188	312 Added 5.31%	6,183 $662,000
Q3 2021 Nov 15, 2021	BUY	$80.98 - $109.47 $293,795 - $397,157	3,628 Added 161.75%	5,871 $604,000
Q2 2021 Aug 16, 2021	BUY	$82.78 - $101.0 $185,675 - $226,543	2,243 New	2,243 $197,000
Q4 2020 Feb 17, 2021	SELL	$92.08 - $124.48 $302,574 - $409,041	-3,286 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$66.45 - $92.7 $58,874 - $82,132	886 Added 36.92%	3,286 $305,000
Q2 2020 Aug 14, 2020	BUY	$57.09 - $79.27 $118,005 - $163,851	2,067 Added 620.72%	2,400 $187,000
Q1 2020 May 13, 2020	BUY	$48.11 - $82.22 $7,360 - $12,579	153 Added 85.0%	333 $19,000
Q4 2019 Feb 14, 2020	BUY	$66.73 - $82.59 $12,011 - $14,866	180 New	180 $14,000

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Canada Pension Plan Investment Board, based on Form 13F filings with the SEC.

Stay updated on Canada Pension Plan Investment Board with notifications on news.